Published in J Clin Pathol Suppl (Assoc Clin Pathol) on January 01, 1976
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 7.47
Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res (1971) 4.61
N.A.S. symposium: new evidence as the basis for increased efforts in cancer research. Proc Natl Acad Sci U S A (1972) 3.28
Gonadotropin-producing anaplastic large-cell carcinomas of the lung. N Engl J Med (1966) 2.27
Foetal "antigens" in cancer. Nature (1972) 1.95
Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med (1971) 1.69
Ectopic ACTH production in carcinoma of the lung. J Clin Invest (1974) 1.65
Ectopic hormone production by non-endocrine tumours. Clin Endocrinol (Oxf) (1974) 1.56
Pancreatic cholera due to production of gastric inhibitory polypeptide. Lancet (1972) 1.44
Ectopic growth-hormone production and osteoarthropathy in carcinoma of the bronchus. Lancet (1968) 1.35
Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas. Gut (1971) 1.33
Production of vasopressin by anaplastic oat cell carcinoma of the bronchus. Clin Sci (1966) 1.33
New observations on the Regan isoenzyme of alkaline phosphatase in cancer patients. Cancer (1971) 1.28
Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology (1968) 1.24
Cytochemical evidence for an ultimobranchial origin of rodent thyroid C cells. Nature (1967) 1.22
Tumor and plasma ACTH concentrations in patients with and without the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1972) 1.21
Subunits of human chorionic gonadotropin: unbalanced synthesis and secretion by clonal cell strains derived from a bronchogenic carcinoma. Proc Natl Acad Sci U S A (1973) 1.19
Biologic and immunologic characterization and physical separation of ACTH and ACTH fragments in the ectopic ACTH syndrome. J Clin Invest (1973) 1.17
Synthesis and release of human growth hormone from lung carcinoma in cell culture. Lancet (1972) 1.08
Biosynthesis of vasopressin in vitro and ultrastructure of a bronchogenic carcinoma. Patient with the syndrome of inappropriate secretion of antidiuretic hormone. J Clin Invest (1972) 1.07
Evidence for the presence of immunoreactive growth hormone in cancers of the lung and stomach. Cancer (1972) 1.07
Plasminogen-activator-producing tumour. Br Med J (1969) 1.07
Endocrine tumours of neural crest origin: neurolophomas, apudomas and the APUD concept. Med Biol (1974) 0.96
Evidence for the presence of tumor peptides with corticotropin-releasing-factor-like activity in the ectopic ACTH syndrome. N Engl J Med (1971) 0.95
Plasma growth hormone and hypertrophic osteoarthropathy in carcinoma of the bronchus. Acta Med Scand (1970) 0.94
Urine and blood serum muramidase (lysozyme) in patients with urogenital tumors. Eur J Cancer (1971) 0.93
Ectopic production of prolactin. N Engl J Med (1971) 0.91
Stimulation of growth hormone release from superfused rat pituitary by extracts of hypothalamus and of human lung tumours. J Endocrinol (1973) 0.88
On the presence of immunoreactive growth hormone in a bronchogenic carcinoma. Australas Ann Med (1969) 0.85
Sexual precocity attributable to ectopic gonadotropin secretion by hepatoblastoma. Am J Med (1973) 0.85
Isolation of growth hormone-releasing hormone(GRH) from porcine hypothalami. Endocrinology (1969) 0.83
Medullary carcinoma of the thyroid--a cause of Cushing's syndrome: report of two cases. J Clin Endocrinol Metab (1968) 0.80
Evidence for the presence of neurophysin in tumors producing the syndrome of inappropriate antidiuresis. J Clin Endocrinol Metab (1972) 0.79
The role of immunology in human cancer research. Can Med Assoc J (1970) 0.77
Growth hormone and prolactin secretion in the carcinoid syndrome. Am J Med Sci (1975) 0.76
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Therapeutic approaches to bone diseases. Science (2000) 5.60
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A (1990) 4.40
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int (1981) 3.77
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology (1989) 2.83
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone (2002) 2.40
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Malignant glaucoma after laser iridotomy. Ophthalmology (1992) 2.28
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res (1991) 2.26
Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature (2000) 2.13
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology (2001) 1.98
Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br J Haematol (1996) 1.79
Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology (1998) 1.75
A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology (1998) 1.75
Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest (1986) 1.73
Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem (2005) 1.71
Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int (1999) 1.69
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone (1999) 1.66
Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology (2001) 1.66
The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res (1998) 1.65
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology (2000) 1.61
Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res (1990) 1.61
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest (1993) 1.58
Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 1.54
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52
IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol (2001) 1.52
Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res (2001) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet (1993) 1.45
Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res (1983) 1.38
Calcitonin gene-related peptide stimulates cyclic AMP formation in rat aortic smooth muscle cells. Biochem Biophys Res Commun (1985) 1.38
Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum (2000) 1.37
Structure of the 5' flanking region of the gene encoding human parathyroid-hormone-related protein (PTHrP). Gene (1989) 1.31
Calcitonin receptor antibodies in the identification of osteoclasts. Bone (1999) 1.29
Functional properties of hormonally responsive cultured normal and malignant rat osteoblastic cells. Endocrinology (1981) 1.29
Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res (1989) 1.28
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem (2001) 1.28
Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res (2000) 1.25
Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line. Cancer Res (1980) 1.24
Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha. J Biol Chem (1999) 1.24
The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med (1996) 1.24
Insulin inhibition of protein degradation in cell monolayers. J Cell Physiol (1980) 1.23
1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet (1980) 1.22
Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci (2000) 1.22
Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone (2010) 1.21
Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol (1993) 1.18
Calcitonin. Curr Med Chem (1999) 1.18
Phosphaturic effect of thyrocalcitonin. Lancet (1966) 1.17
Parathyroid hormone-related protein and hypercalcemia. Cancer (1997) 1.17
PC8 [corrected], a new member of the convertase family. Biochem J (1996) 1.16
Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology (1997) 1.16
The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. J Biol Chem (2000) 1.15
Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res (1992) 1.14
Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcif Tissue Int (1985) 1.14
Endothelium and the vasodilator action of rat calcitonin gene-related peptide (CGRP). Br J Pharmacol (1987) 1.14
Hypercalcemia of malignancy. Rev Endocr Metab Disord (2000) 1.13
Induction of calcitonin receptors by 1 alpha, 25-dihydroxyvitamin D3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology (1988) 1.13
The mode of action of thyrocalcitonin. Lancet (1966) 1.13
Organized sports for children and preadolescents. Pediatrics (2001) 1.12
Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol (1990) 1.12
Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab (1991) 1.11
Effect of guanyl nucleotides on parathyroid hormone-responsive adenylate cyclase in chick kidney. J Endocrinol (1976) 1.10
The effects of intravenous heroin administration on extracellular nucleus accumbens dopamine concentrations as determined by in vivo microdialysis. J Pharmacol Exp Ther (1995) 1.10
Human beta-thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells. Nature (1979) 1.09
Receptors for 1,25(OH)2-vitamin D3 enriched in cloned osteoblast-like rat osteogenic sarcoma cells. FEBS Lett (1980) 1.08
In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res (1994) 1.08
Synthesis and release of human growth hormone from lung carcinoma in cell culture. Lancet (1972) 1.08
Cloning of an osteoblastic cell line involved in the formation of osteoclast-like cells. J Cell Physiol (1990) 1.08
Effects of nucleotides, hormones, ions, and 1,25-dihydroxycholecalciferon on 1,25-dihydroxycholecalciferol production in isolated chick renal tubules. Clin Sci Mol Med (1974) 1.08
Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Mol Cell Endocrinol (1993) 1.07
Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines. Cancer Res (1980) 1.06
Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth (1993) 1.06
Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. J Endocrinol (1988) 1.06
Leukemia inhibitory factor: a novel bone-active cytokine. Endocrinology (1990) 1.05
mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol (2001) 1.05
Rat osteogenic sarcoma cells: comparison of the effects of prostaglandins E1, E2, I2 (prostacyclin), 6-keto F1alpha and thromboxane B2 on cyclic AMP production and adenylate cyclase activity. Biochem Biophys Res Commun (1978) 1.04
Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. Endocrinology (1996) 1.04
Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma. Nature (1976) 1.03
Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol (1990) 1.02
Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone (1997) 1.02
Calcitonin-responsive adenylate cyclase in a calcitonin-producing human cancer cell line. Br J Cancer (1977) 1.02
Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest (1988) 1.01
Endogenous Gs-coupled receptors in smooth muscle exhibit differential susceptibility to GRK2/3-mediated desensitization. Biochemistry (2008) 1.01
Parathyroid hormone metabolism in man: effect of nephrectomy. Clin Sci (1969) 1.00
The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res (1999) 1.00
CPAP therapy via oronasal mask for obstructive sleep apnea. Chest (1994) 1.00
Parathyroid hormone-related protein (PTHrP) and hypercalcaemia. Eur J Cancer (1998) 1.00
Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets. Biochim Biophys Acta (1979) 0.99